The global multiplex assays market is anticipated to grow at a CAGR of 14.8% during the forecast period (2023-2030). Multiplex assays have many applications in clinical diagnostics, drug discovery & development, genomics & molecular biology, proteomics & protein analysis, and immunology & infectious disease research. They are used for detecting and quantifying biomarkers, understanding drug mechanisms, gene expression analysis, genotyping, and studying immune responses. Furthermore, the market’s growth is attributed to advancements in CAR-T therapy around the globe. CAR-T therapy has proven immense potential in the treatment of certain forms of cancer. Accurate monitoring and comprehension of CAR-T cell populations is essential for improving therapeutic efficacy and patient outcomes. This assay's capacity to completely rapidly quantify CAR-T cells can improve therapy monitoring and decision-making in clinical settings. For instance, in June 2023, Navigate BioPharma Services, Inc., launched new multiplex digital PCR assays for comprehensive quantification of multiple chimeric antigen receptor (CAR) T cells, CAR-T therapy is a form of cancer immunotherapy that uses genetically modified T cells to recognize and fight certain kinds of cancer. The multiplex digital PCR assay can measure the number, function and persistence of CAR-T cells quickly and accurately, detecting as low as 0.01%. It can be done in less than two hours, without requiring a standard curve.
Browse the full report description of “Multiplex assays Market Size, Share & Trends Analysis Report by Type (Protein Multiplex Assays, Nucleic Acid-Based Multiplex Assays, and Cell-based Multiplex Assays), by Technology (Multiplex Real-Time PCR, Luminex Bead Technology, Flow Cytometry, and Others), and by End-User (Pharmaceutical and Biopharmaceutical Companies, Contract Research Organizations (CROs), Research and Academic Institutions, Others), Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/multiplex-assays-market
Furthermore, FluoroType mycobacteria is a multiplex assay that allows for the diagnosis of multiple pathogens in a single sample, that is beneficial in terms of time and resources. This advanced diagnostic capability is especially desired in the management of tuberculosis and mycobacterial infections. For instance, in April 2022, Bruker Launched Unique LiquidArray Multiplex PCR Assays. The FluoroCycler XT thermocycler with high precision. FluoroType Mycobacteria employs innovative LiquidArray technology to distinguish 31 clinically significant non-tuberculous mycobacteria and the M. tuberculosis complex from cultures in a single test. It adds to company’s extensive portfolio in tuberculosis (TB) and mycobacteria, that incorporates identification, differentiation, and drug resistance testing.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Type
o By Technology
o By End-User
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- includes Bio-Rad Laboratories, Inc., Merck Group, PerkinElmer U.S. LLC, Quansys Biosciences Inc., Thermo Fisher Scientific Inc., among others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Multiplex assays Market Report Segment
By Type
By Technology
By End-User
Global Multiplex assays Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/multiplex-assays-market